Drug intelligence / Profile preview

TK-4204

Development stage: Preclinical
Lead developer: T-knife
Modality: Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

TK-4204 is an in vivo chimeric antigen receptor (CAR) cell therapy in preclinical development for the treatment of gastrointestinal (GI) cancers. Developed by T-knife Therapeutics, the therapy utilizes a novel multi-armoring approach, incorporating a FAS-TGF-beta converter and secreted bispecific T-cell engager (BiTE) armoring to enhance T-cell survival, persistence, and efficacy within the immunosuppressive tumor microenvironment. The specific CAR target remains undisclosed, and the program is currently in the discovery/preclinical stage.

Beyond the preview

Go deeper on TK-4204.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TK-4204.

Explore the full profile